Background. Isolated limb infusion (ILI) is a therapeutic option for patients with recurrent, unresectable extremity malignancies. Methods. A prospectively collected single-institution database of patients undergoing ILI was analyzed for preoperative, intraoperative, and postoperative parameters and outcomes. Results. From May 2007 to January 2012, a total of 76 patients successfully underwent initial ILI, and 28 after either previous hyperthermic isolated limb perfusion or ILI. Seventy-nine patients (74 %) had melanoma, 24 (22 %) sarcoma, 3 (3 %) Merkel cell, and 1 (1 %) squamous cell carcinoma. There were 55 (72 %) initial and 22 (79 %) repeat lower extremity (LE) ILIs, and 21 (78 %) initial and 6 (22 %) repeat upper extremity (UE) ILIs. Serologic toxicity, measured by serum creatine kinase (CK), peaked higher and later in LE ILIs, median 620 versus 124 IU/L, and postoperative day 4 versus 2, respectively (P \ 0.05). LE ILIs had a longer hospital length of stay (LOS), median 6 versus 5 days (P \ 0.0001). A median grade II Wieberdink regional toxicity was observed. Three-month follow-up was available in 94 (90 %). A response (overall response rate, ORR) was seen in 72 % of ILIs performed for melanoma and 58 % for sarcoma. 
INTRODUCTION
Isolated limb infusion (ILI) is a less invasive method of delivering regional therapy for limb preservation when compared with the open technique of hyperthermic isolated limb perfusion (HILP). ILI was first adapted from HILP by Thompson et al. in the early 1990's to treat in-transit, unresectable melanoma of the extremities. 1 More recently, ILI has been utilized in treating unresectable extremity soft tissue sarcoma and other cutaneous malignancies, although published series demonstrate varying results. 2, 3 A single-institution series describing the experience from the Melanoma Institute Australia demonstrated overall response (complete response and partial response) rates of 84 % after ILI for melanoma and 90 % for sarcoma. 2, 4 Of note, the Australian experience for melanoma includes treatment of stage I-II melanoma with ILI. 4 Multivariate analysis demonstrated only a complete response to be predictive of long-term survival, and stage was not predictive of disease response. 5 Although singleinstitution series in the United States are not as robust, a multi-institutional review of patients treated for stage III/ IV extremity melanoma demonstrated an overall response rate (ORR) of 64 % (31 % complete response, 33 % partial response). 6 Because significant variability exists in patient selection and ILI technique, response rates may be affected by the heterogeneity among the reported series. The current study aims to evaluate a single-institution cohort of patients treated with ILI for in-transit melanoma metastases of the extremity, unresectable or maximally treated soft tissue sarcoma, or other cutaneous malignancies, performed under nearly uniform conditions.
METHODS
A prospectively maintained database of patients undergoing ILI at our institution was reviewed for indication for limb infusion, patient demographics, intraoperative and perioperative parameters, and postoperative outcome.
Statistical Analyses
All data analyses were performed with SAS (version 9.2; SAS Institute Inc., Cary, NC), with significance considered at the two-sided P value of B0.05. Data were natural log transformed before applying parametric tests, and generalized linear mixed models or multivariate models applied where applicable.
Operative Technique
Each limb infusion involved placement of 5F arterial and 6F venous catheters to the affected limb under fluoroscopic guidance via a percutaneous approach. The patient was systemically heparinized with 300 units per kg body weight to achieve an activated clotting time (ACT) of greater than 400 s. Under general anesthesia in the operating room, 60 mg of Papaverine was administered into the ILI circuit after the tourniquet was inflated to 250 mmHg for upper extremities and 300 mmHg for lower extremities. Actinomycin-D (100 lg/L) and melphalan (7.5 mg/L for LE and 10 mg/L for UE) were dose-based on limb volume. Melphalan dose was further corrected on the basis of the patient's ideal body weight (IBW) as follows: [Dose (mg) 9 Limb volume (L) 9 IBW]/Actual body weight. The majority (90 %) had chemotherapy dose correction for IBW. Chemotherapy was circulated for 30 min while the extremity was externally warmed to greater than 37°C. The limb was washed out with saline before tourniquet release.
Postoperative Follow-up
Patients were monitored with daily physical examination of the extremity and twice daily assessment of creatine kinase (CK) levels, a measure of systemic toxicity. If CK levels peaked above 1000 IU/L, intravenous dexamethasone and normal saline infusion was initiated in an effort to decrease the acute inflammatory reaction in the affected extremity and prevent rhabdomyolysis-induced acute tubular necrosis. Once the CK level peaked, patients were discharged. If patients did not exhibit a CK elevation or limb toxicity, they were generally discharged on postoperative day 4. All patients received routine deep vein thrombosis prophylaxis with Fragmin 5,000 units subcutaneous injection daily while hospitalized and were discharged home on aspirin 325 mg daily for 3 months.
Patients were seen in follow-up at 2, 6 and 12 weeks after ILI. Response to treatment was judged by clinical assessment of disease burden and PET/CT. Clinical assessment was used for dermal and cutaneous lesions; PET/CT imaging was routinely obtained 3 months after ILI to assess for both regional response and distant disease, in keeping with an algorithm previously published by Beasley et al. 7 Complete response (CR) was defined as resolution of all nodules; partial response (PR) as a C30 % decrease in diameter or disappearance of at least 30 % of the nodules in field; stable disease (SD) was failure to meet criteria for PR but without progression of disease; and progressive disease (PD) was at least a 20 % increase in diameter of disease nodules or progression of disease as evidenced by new nodules after ILI. ORR was defined as the number of patients with CR or PR in the cohort.
As described by Chai et al., an algorithm was proposed for repeat ILIs. 8 Repeat ILI was generally offered for patients who had a CR or PR after initial HILP or ILI with duration of response [3 months before disease recurrence or progression. 8 
Outcome
Clinical response to ILI was determined at 3 months after ILI. Because melanoma and sarcoma represented the majority of patients, clinical response is reported here for those two groups. Ninety-four procedures were evaluated.
RESULTS

Patient Cohort
From May 2007 to January 2012, a total of 107 patients underwent attempted ILI at our institution. Three procedures (3 %) were terminated before ILI was performed. In one patient, the tourniquet failed to achieve arterial occlusion in the affected limb. In one patient, the vessels were too small or tortuous and would not accommodate a 5F or 6F sheath, and one patient sustained an arterial intimal flap upon placement of the catheters, and the ILI was not performed. Of the 104 ILIs performed, the majority of patients were women (n = 63, 59 %) with a median age of 73 (range 19-92) years. Seventy-nine patients (74 %) had in-transit melanoma metastases not amenable to surgical resection. Twenty-four (22 %) had unresectable extremity sarcoma; multiple histologic subtypes were treated, most commonly high-grade undifferentiated pleomorphic sarcoma (n = 11, 46 %) and Kaposi sarcoma (n = 3, 13 %). Less common indications included Merkel cell carcinoma (3, 3 %) and squamous cell carcinoma (n = 1, 1 %), Table 1 .
Seventy-six patients underwent ILI as an initial regional therapeutic procedure; of these, 55 (72 %) were in the lower extremity (LE) and 21 (28 %) in the upper extremity (UE). Twenty-eight patients underwent a repeat regional therapeutic procedure as an ILI after either an initial HILP or ILI, 22 (79 %) of whom had LE disease and 6 (21 %) with UE disease (Fig. 1 ).
Intraoperative and Perioperative Parameters
Although the standard circulation time for chemotherapy was 30 min for all patients, total ischemia time varied as a result of time to prime the ILI circuit, ensuring adequate tourniquet occlusion, achieving limb temperature [37°C before chemotherapy instillation, and washout of the limb after a 30 min infusion. Median ischemic time for the overall cohort was 50 (range 42-82) min. There was no difference in ischemia time between LE and UE ILI (P = 0.70), or in initial versus repeat ILI (P = 0.39) ( Table 2 ).
The median base excess, seen on perfusate blood gas analysis, as well as the median perfusate pH at 30 min, were evaluated. The overall cohort had a median perfusate base excess of -9 mEq/L (range -3 to -22.8) with a median pH at 30 min of 7.2 (range 6.92-7.72). UE ILIs had greater base excess when compared to LE procedures, -14 versus -8 mEq/L, and were associated with a lower pH, 7.1 versus 7.21, P \ 0.001. Repeat UE and LE ILIs did not exhibit greater base excess than initial infusions, median -13 versus -14 mEq/L and -8 versus -8 mEq/L, respectively. Repeat ILIs were not associated with any difference in pH than initial ILIs, P = 0.99 (Table 2) .
Postoperatively, serologic toxicity was assessed by measurement of CK levels. Although the median peak CK level for the cohort was 421 (range 21-9626) IU/L, LE procedures achieved a higher peak CK level than UE procedures, 620 versus 124 IU/L, P = 0.001. Repeat LE procedures tended to achieve an even higher peak CK level, median 963 IU/L. Repeat UE procedures exhibited similar peak CK levels as initial ILIs, 122 versus 124 IU/L, respectively. LE ILIs achieved a peak CK level on a later postoperative day than UE ILIs, day 4 versus 2, P \ 0.05. There was no difference in day of peak CK level when comparing initial ILI versus repeat ILI, P = 0.46 (Table 2) .
Overall median length of stay was 6 days for the cohort and was shorter for UE ILIs versus LE, median 5 versus 6 days, P \ 0.0001. Repeat ILIs were not associated with any longer length of hospital stay, P = 0.44. A median Wieberdink grade 2 toxicity was seen in the overall cohort (range 1-3). Twenty-four patients (23 %) had Wieberdink grade 3 toxicity, 23 (96 %) occurring in LE ILIs and 1 (4 %) in an UE ILI. LE ILIs exhibited greater toxicity than UE ILIs, P = 0.0004 (Table 2) . Repeat perfusions were not found to have a significant increase in toxicity, and no patients required fasciotomy or had treatment-related limb loss (Wieberdink grade 4 or 5 toxicity).
Complications were seen in four patients (4 %) within a 30-day period. This included three patients (3 %) who developed a deep vein thrombosis in the affected limb. All patients were treated with anticoagulation and did not experience any adverse consequences. One patient (1 %) developed an ischemic stroke immediately after the procedure. With the exception of this patient who had residual hemiparesis of the UE nearly 6 months after ILI, no patients had long-term toxicity or sequelae after ILI.
Response to ILI in Melanoma Patients
Overall, a CR was achieved in 32 % of ILIs for melanoma, and a PR was seen in 40 %. Ten percent of melanoma ILIs demonstrated SD. Eighteen percent of melanoma had PD after ILI (Fig. 2) . When examining response by LE versus UE as well as by initial versus repeat ILI, CR was seen in 35 % of initial LE ILIs for melanoma; repeat LE ILI had a 21 % CR. UE ILIs for melanoma achieved a 42 % initial CR and a 25 % repeat CR (Table 3) .
Partial response was seen in approximately one third of patients who underwent initial ILI in either LE (38 %) or UE (33 %) for melanoma. PR was seen more often in repeat infusions (ILI after initial ILI or HILP) for melanoma, with 42 and 75 % of LE and UE repeat ILIs achieving PR, respectively.
Stable disease (SD) was seen in 8 % of melanoma patients who underwent initial LE or UE ILIs. Sixteen percent and 0 % of the repeat LE and UE ILIs, respectively, had SD. Similar proportions of patients with melanoma demonstrated PD after undergoing initial ILI, 19 and 17 % for LE and UE, respectively. Repeat infusions demonstrated similar PD response in LE ILIs, 21 %, but none of the repeat UE ILIs had PD (Table 3 ).
Response to ILI in Sarcoma Patients
Overall, a CR was seen in 16 % of ILIs performed for sarcoma. Partial response was seen in 47 %. None of the sarcoma ILIs had SD, and 37 % had PD after ILI.
When examining disease response by LE versus UE and initial versus repeat disease, response in ILIs performed for sarcoma appeared to demonstrate less favorable outcomes, with a 23 and 0 % CR for initial and repeat LE ILIs, respectively, although was not statistically significant. Complete response was not achieved in any UE ILI performed for sarcoma (Table 3) .
Sarcoma patients had greater proportions of patients achieving PR than melanoma patients, seen in 31 and 50 % of initial LE and UE ILIs, respectively. Although there were only four sarcoma patients who underwent repeat infusions, they achieved PR rates of 67 and 100 % in repeat LE and UE ILIs, respectively (Table 3) . None of the patients with sarcoma who underwent ILI had stable disease, either demonstrating disease response or disease progression. Progressive disease was seen in nearly half (46 and 50 % for LE and UE, respectively) of patients who had an initial ILI for sarcoma. Repeat infusions, however, demonstrated disease progression in one of the three LE sarcoma patients (33 %). None of the UE patients had PD.
ORR between LE versus UE ILIs (P = 0.44, 95 % confidence interval 0.17-2.12), or initial versus repeat ILIs (P = 0.9, 95 % confidence interval 0.47-2.34), was not significantly different in either the melanoma or sarcoma groups.
DISCUSSION
Development of in-transit melanoma metastases is generally perceived to be an indicator of aggressive biologic behavior in cutaneous melanoma and presents a therapeutic conundrum. Classified as stage III disease by the American Joint Committee on Cancer Staging (AJCC), in-transit metastases are seen to develop in 2-3.5 % of sentinel lymph node-negative patients and up to 12 % of sentinel lymph node positive patients.
9-11 Development of in-transit metastases is associated with a median overall 5-year survival of 54 %. 11 Management is controversial, ranging from hyperthermic limb perfusion or ILI to local intratumoral injections to systemic therapy, with no therapy definitively improving overall survival (OS). 12, 13 Locally advanced or unresectable soft tissue sarcoma, likewise, poses a similar challenge, with amputation historically being the treatment option of choice. Limb salvage options, including regional therapy with hyperthermic limb perfusion and ILI have been proposed with limb salvage rates of up to 80 % but also without definitive effect on OS. 14, 15 Isolated limb perfusion (ILP) was first introduced as a regional therapy in the 1950s, designed to achieve higher concentrations of chemotherapy in the extremity than what could be achieved via systemic administration while avoiding toxicity. 12, 16, 17 Hyperthermia to the extremity was introduced in the 1960s, with improved response rates compared to normothermic perfusion. 18, 19 ILI was presented as a simpler, less morbid alternative to HILP. 1 Although the Melanoma Institute Australia experience reports comparable ORR and duration of response with ILI for melanoma compared with conventional HILP (84 % ORR with ILI compared with 85 % with ILP), the CR rate was higher for HILP than ILI (69 vs. 38 %, respectively). 4, 5 One single-institution U.S. series reported a lower ORR with ILI versus HILP, 44 % ORR with ILI versus 88 % with HILP. 20 However, more recent series have shown improved results with ILI for melanoma, with ORR up to 88 %. 6 It may not be valid to compare the U.S. experience with the Australians, as the U.S. excludes early 2, 3 Combination with external beam irradiation has been described, achieving limb salvage in 83 %. 21 Although these results are encouraging, soft tissue sarcoma encompasses an enormous range of histologic subtypes, with varying biologic and clinical behaviors. Our experience with soft tissue sarcoma and ILI showed an ORR of 63 %.
Previous reports of patients who underwent repeat ILI procedures for melanoma showed ORR ranging from 33 to 83 %. 8, 22 The Melanoma Institute Australia demonstrated an ORR of 83 % and a CR of 23 % after repeat ILI. Their cohort, however, included early stage melanoma and planned double ILI procedures. 22 Chai et al. reported a multi-institutional U.S experience with repeat ILI after initial ILI and found an ORR of 40 % and a CR rate of 24 %. 8 Data regarding repeat ILI for sarcoma are quite limited. Our experience with repeat ILI for melanoma demonstrated improved ORR for repeat UE ILI (ORR of 100 %) whereas repeat LE ILI had a lower ORR when compared with initial ILI (63 vs. 73 %, respectively). Complete response rates were similar between repeat UE and LE ILIs. Repeat ILI for sarcoma likewise appeared to have improved ORR compared with initial ILI, with repeat UE ILI achieving a 100 % ORR, although the cohort size was small. Despite an improved ORR, there was no CR in repeat ILIs performed for sarcoma.
Although ORR vary between institutions, toxicity and complications were shown to be lower with ILI than with ILP, an advantage for ILI. 22 In one U.S. single-institution study comparing ILI to ILP, ILI had 0 % treatment-related limb loss versus a 3 % risk with ILP. This same study also reported a 4 % development of deep vein thrombosis with ILI versus 11 % with ILP. Twenty percent of the ILI cohort also developed grade 3 or higher Wieberdink toxicity, whereas ILP was associated with a 27 % risk of grade 3 or higher toxicity. 23 The Melanoma Institute Australia recently reported a 0 % limb loss rate with ILI for melanoma, but observed a 35 % rate of grade 3 or higher toxicity. 24 Santillan et al. found toxicity after ILI to be associated with female sex, papaverine, and high peak CK levels. Adjustment of the melphalan dose for IBW, however, was significantly associated with lower toxicity. 25 In this study, we also report a 0 % limb loss rate. The median CK level increased with repeat LE ILI, and we found higher toxicity in LE ILIs than UE ILIs. UE ILIs demonstrated an earlier peak CK level and significantly shorter hospital length of stay. There was no difference in hospital length of stay for repeat infusions, either UE or LE. No patient experienced any major adverse toxicity from ILI.
Even in the modern era of melanoma treatment, HILP appears to improve OS in only a small subset of patients, with a 34 % 10 years actuarial survival. 26 As there have been no prospective trials comparing ILP to ILI, it is difficult to determine whether the two modalities are equivalent. The Duke University experience, when retrospectively analyzed, found no difference in OS in patients treated with either HILP or ILI over 15 years. 23 One must note that a fair comparison between ILI and HILP was not made in that review because disease burden and techniques differed, and the review was not performed in the context of a randomized clinical trial. However, a survival benefit was seen in patients who attained a CR with treatment, either HILP or ILI. 23 In this study, we demonstrate that ILI may achieve ORR of 50-75 %, depending on the indication and extremity, with CR achieved in up to 42 %. ILI performed for sarcoma achieves similar ORR as melanoma, and repeat infusions offer similar response rates as initial infusions. It is important, however, to note that although advanced extremity sarcoma patients have few treatment options available, melphalan-based ILI offers a greater potential benefit to melanoma patients. Although repeat UE ILIs appeared to offer clinical benefit, with no patients demonstrating disease progression, the sample size was small.
In conclusion, ILI is an effective alternative to ILP and may be successfully performed for the majority of extremity in-transit melanoma metastases, unresectable soft tissue sarcoma and other nonmelanoma cutaneous neoplasms. Repeat ILI is feasible, with a similar toxicity profile as initial ILI, and offers similar disease response rates. UE ILIs may have an improved disease response and warrants further investigation. Because of the low complication rate and 0 % amputation rate, ILI presents an attractive treatment modality and should be incorporated into the therapeutic armamentarium. Further investigation is warranted to define its true effect on OS.
